Nelsa González-Aguado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nelsa González-Aguado has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Costa
Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina; A.O.U. Policlinic “G. Martino” , Messina
6 shared publications - Alejandro Isidoro Pérez Cabeza
Department of Cardiology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
4 shared publications - Francisco Javier Pavón
Instituto de Investigación Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Malaga, Spain
4 shared publications - Alberto Piserra-López
Department of Medicine, UMA, Heart Area, Hospital Universitario Virgen de la Victoria, CIBERCV, IBIMA Plataforma BIONAND, Malaga, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain., Spain
3 shared publications - Arancha Díaz Expósito
Department of Cardiology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
3 shared publications - Fernando Puyol-Ruiz
Department of Medicine, UMA, Heart Area, Hospital Universitario Virgen de la Victoria, CIBERCV, IBIMA Plataforma BIONAND, Malaga, Spain., Spain
3 shared publications
Latest Publications
- 29 May 2026
- Published by IOP Publishing in Physiological Measurement
- Vol. 47 (5) , 055023
BIVA and VExUS for hydration assessment and cardiovascular mortality prediction in cardiorenal patients
Objectives . Despite advances in pharmacological treatment, heart failure (HF) remains a leading cause of hospitalization, mortality, and healthcare costs. HF often coexists with chronic kidney disease (CKD), impacting diagnosis, prognosis, and treatment. This study aims to evaluate correlations between bioelectrical impedance vector analysis (BIVA), ultrasound via VExUS, biomarkers (Ca125), and clinical outcomes assessing congestion and predicting cardiovascular mortality in patients with cardiorenal syndrome (CRS). Approach . This prospective observational study included 85 patients with HF and CKD assessed at the Endocardiorenal Unit of Virgen de la Victoria University Hospital. Patients underwent a comprehensive evaluation including BIVA (AKERN BIA 101 BIVA® device), ultrasound assessment (General Electric Vivid T8 system device) for VexUS evaluation, and biomarkers (Ca125, NT-proBNP). BIVA measurements were taken using a 50 kHz phase-sensitive impedance analyzer to measure resistance ( R ) and reactance ( X c). Statistical analysis involved Pearson’s correlation and Cox regression to determine the relationships between these methods and mortality risk. Main results . Among the 85 patients (mean age 75.2 ± 8.4 years, 58.8% men), 11 cardiovascular and 8 non-cardiovascular deaths occurred over a 12-month follow-up. Strong statistically significant association was found between age, low hemoglobin levels, NYHA dyspnea, and mortality. Moderate statistically significant association was observed between BIVA hydration (HYDRAGRAM® calculated by device) and VExUS ( r = 0.51, p < 0.001), with a hydration cut-off point of 78.7% predicting cardiovascular mortality. There was also a significant association between reactance ( p = 0.03) and phase angle (PhA) ( p = 0.006) with mortality. Cox regression analysis showed that patients with higher hydration had 5.43 times the risk of mortality compared to those with lower hydration (HR = 5.43, 95% CI: 1.36-21.61, p = 0.016). Significance . Integrating BIVA, VExUS, and Ca125 effectively assesses congestion in CRS patients. A BIVA-derived hydration threshold >78.7% was independently associated with 12-month cardiovascular mortality, supporting its value for risk stratification and improving patient management.
- 29 May 2026
- Published by IOP Publishing in Physiological Measurement
- Vol. 47 (5) , 055023
BIVA and VExUS for hydration assessment and cardiovascular mortality prediction in cardiorenal patients
Objectives . Despite advances in pharmacological treatment, heart failure (HF) remains a leading cause of hospitalization, mortality, and healthcare costs. HF often coexists with chronic kidney disease (CKD), impacting diagnosis, prognosis, and treatment. This study aims to evaluate correlations between bioelectrical impedance vector analysis (BIVA), ultrasound via VExUS, biomarkers (Ca125), and clinical outcomes assessing congestion and predicting cardiovascular mortality in patients with cardiorenal syndrome (CRS). Approach . This prospective observational study included 85 patients with HF and CKD assessed at the Endocardiorenal Unit of Virgen de la Victoria University Hospital. Patients underwent a comprehensive evaluation including BIVA (AKERN BIA 101 BIVA® device), ultrasound assessment (General Electric Vivid T8 system device) for VexUS evaluation, and biomarkers (Ca125, NT-proBNP). BIVA measurements were taken using a 50 kHz phase-sensitive impedance analyzer to measure resistance ( R ) and reactance ( X c). Statistical analysis involved Pearson’s correlation and Cox regression to determine the relationships between these methods and mortality risk. Main results . Among the 85 patients (mean age 75.2 ± 8.4 years, 58.8% men), 11 cardiovascular and 8 non-cardiovascular deaths occurred over a 12-month follow-up. Strong statistically significant association was found between age, low hemoglobin levels, NYHA dyspnea, and mortality. Moderate statistically significant association was observed between BIVA hydration (HYDRAGRAM® calculated by device) and VExUS ( r = 0.51, p < 0.001), with a hydration cut-off point of 78.7% predicting cardiovascular mortality. There was also a significant association between reactance ( p = 0.03) and phase angle (PhA) ( p = 0.006) with mortality. Cox regression analysis showed that patients with higher hydration had 5.43 times the risk of mortality compared to those with lower hydration (HR = 5.43, 95% CI: 1.36-21.61, p = 0.016). Significance . Integrating BIVA, VExUS, and Ca125 effectively assesses congestion in CRS patients. A BIVA-derived hydration threshold >78.7% was independently associated with 12-month cardiovascular mortality, supporting its value for risk stratification and improving patient management.
- Open Access
- 27 April 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (5) , 183
In Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI)
Bleeding risk assessment is a critical component of the management of patients with ST-segment elevation myocardial infarction (STEMI), yet the optimal approach to risk stratification remains controversial. Although several bleeding risk scores have been developed, their predictive performance in STEMI populations is still evolving. Importantly, bleeding risk in STEMI is dynamic and influenced by clinical status, procedural factors, and antithrombotic strategies, underscoring the need for continuous reassessment throughout hospitalization. Bleeding avoidance measures—including radial access, judicious use of anticoagulation, and individualized antiplatelet therapy—play a pivotal role in reducing complications. Balancing ischemic and hemorrhagic risks is particularly challenging in patients with concomitantly high thrombotic and bleeding risks, requiring tailored management strategies. As bleeding remains a major determinant of prognosis, refining risk stratification tools and integrating evidence-based bleeding prevention strategies into clinical practice are essential. This narrative review summarizes the current evidence regarding the identification of high bleeding risk in hospitalized patients with STEMI and discusses its clinical implications. Also, this review proposes a dynamic, phase-specific framework for in-hospital bleeding risk assessment and management in patients with STEMI.
- 27 April 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (5) , 183
Open AccessIn Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI)
Bleeding risk assessment is a critical component of the management of patients with ST-segment elevation myocardial infarction (STEMI), yet the optimal approach to risk stratification remains controversial. Although several bleeding risk scores have been developed, their predictive performance in STEMI populations is still evolving. Importantly, bleeding risk in STEMI is dynamic and influenced by clinical status, procedural factors, and antithrombotic strategies, underscoring the need for continuous reassessment throughout hospitalization. Bleeding avoidance measures—including radial access, judicious use of anticoagulation, and individualized antiplatelet therapy—play a pivotal role in reducing complications. Balancing ischemic and hemorrhagic risks is particularly challenging in patients with concomitantly high thrombotic and bleeding risks, requiring tailored management strategies. As bleeding remains a major determinant of prognosis, refining risk stratification tools and integrating evidence-based bleeding prevention strategies into clinical practice are essential. This narrative review summarizes the current evidence regarding the identification of high bleeding risk in hospitalized patients with STEMI and discusses its clinical implications. Also, this review proposes a dynamic, phase-specific framework for in-hospital bleeding risk assessment and management in patients with STEMI.
- Open Access
- 18 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2325
Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies
Arterial thrombosis emerges from the interplay between plaque disruption, platelet activation, and coagulation pathway amplification on a background of heterogeneous ischemic and bleeding risk. Optimal antithrombotic therapy therefore varies across clinical settings, from acute coronary syndromes (ACS) to chronic coronary syndromes (CCS), ischemic stroke, peripheral artery disease (PAD), and atrial fibrillation (AF) associated with atherosclerotic disease. Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid “one-size-fits-all” dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. In ischemic stroke, short-course DAPT is confined to minor events and transient ischemic attacks, whereas long-term monotherapy remains standard, and the coexistence of AF typically shifts the balance toward oral anticoagulation. Across all scenarios, antithrombotic benefit must be weighed against bleeding, especially in elderly, frail, or comorbid patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care.
- 18 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2325
Open AccessOptimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies
Arterial thrombosis emerges from the interplay between plaque disruption, platelet activation, and coagulation pathway amplification on a background of heterogeneous ischemic and bleeding risk. Optimal antithrombotic therapy therefore varies across clinical settings, from acute coronary syndromes (ACS) to chronic coronary syndromes (CCS), ischemic stroke, peripheral artery disease (PAD), and atrial fibrillation (AF) associated with atherosclerotic disease. Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid “one-size-fits-all” dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. In ischemic stroke, short-course DAPT is confined to minor events and transient ischemic attacks, whereas long-term monotherapy remains standard, and the coexistence of AF typically shifts the balance toward oral anticoagulation. Across all scenarios, antithrombotic benefit must be weighed against bleeding, especially in elderly, frail, or comorbid patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care.
- Open Access
- 4 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1938
Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study
Background: Lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, raising questions regarding the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 h before hospital discharge. Cohort A had follow-up measurements at 4 months and 8 months; Cohort B had them at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: 57.9% of patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. In the multivariable analysis, incomplete revascularization was an independent predictor of high Lp(a) variability (odds ratio (OR) 2.22; 95% confidence interval (CI) 1.14–4.31; p = 0.02) while female sex and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93–4.00; p = 0.08 and OR 11.18; 95% CI 0.79–157.58; p = 0.07, respectively) without reaching statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-year follow-up were 7.9 mg/dL (interquartile range (IQR) 3.0–18.9) and 10.7 mg/dL (IQR 3.0–21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early, targeted, repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.
- 4 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1938
Open AccessIntra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study
Background: Lipoprotein(a) [Lp(a)] is a causal and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, raising questions regarding the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 h before hospital discharge. Cohort A had follow-up measurements at 4 months and 8 months; Cohort B had them at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: 57.9% of patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. In the multivariable analysis, incomplete revascularization was an independent predictor of high Lp(a) variability (odds ratio (OR) 2.22; 95% confidence interval (CI) 1.14–4.31; p = 0.02) while female sex and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93–4.00; p = 0.08 and OR 11.18; 95% CI 0.79–157.58; p = 0.07, respectively) without reaching statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-year follow-up were 7.9 mg/dL (interquartile range (IQR) 3.0–18.9) and 10.7 mg/dL (IQR 3.0–21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early, targeted, repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.
- Open Access
- 24 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1688
Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
Reducing residual cardiovascular risk following acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACEs) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) (Lp(a)) is a pro-inflammatory, prothrombotic, and pro-atherosclerotic lipoprotein that appears to play a major role in residual risk after ACS or ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although their clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions in hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role of Lp(a) as a major contributor to residual cardiovascular risk following ACS.
- 24 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1688
Open AccessImpact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
Reducing residual cardiovascular risk following acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACEs) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) (Lp(a)) is a pro-inflammatory, prothrombotic, and pro-atherosclerotic lipoprotein that appears to play a major role in residual risk after ACS or ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although their clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions in hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role of Lp(a) as a major contributor to residual cardiovascular risk following ACS.
- Open Access
- 14 February 2026
- Published by MDPI AG in Preprints.org
Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study
Background: Lipoprotein(a) [Lp(a)] is a casual and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, questioning the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 hours before hospital discharge. Cohort A had follow-up measurements at 4 months, and 8 months; Cohort B at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: A total of 57.9% patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. At multivariable analysis incomplete revascularization was an independent predictor of high Lp(a) variability (OR 2.22; 95% CI 1.14-4.31; p 0.02) while female sex, and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93-4.00; p 0.08 and OR 11.18; 95% CI 0.79-157.58; p 0.07, respectively) without reaching formal statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-years follow-up were 7.9 mg/dL (IQR 3.0-18.9) and 10.7 mg/dL (IQR 3.0-21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early targeted repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.
- 14 February 2026
- Published by MDPI AG in Preprints.org
Open AccessIntra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study
Background: Lipoprotein(a) [Lp(a)] is a casual and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and is largely genetically determined. However, recent studies indicate significant intra-individual variability, particularly among patients with intermediate Lp(a) levels (30–50 mg/dL). Yet, data on long-term variability are limited, and acute coronary syndrome (ACS) may further influence Lp(a) levels, questioning the optimal timing of assessment after ACS. Methods: We studied 235 ACS patients across two follow-up cohorts. Baseline Lp(a) was measured 24 hours before hospital discharge. Cohort A had follow-up measurements at 4 months, and 8 months; Cohort B at 5 years. Clinically meaningful intra-individual variability was defined as ≥20 mg/dL or ≥25% change. Results: A total of 57.9% patients exhibited clinically significant Lp(a) variability. Changes in risk category occurred in 15.3% of patients in the baseline high-risk group, 60.6% of patients in the intermediate-risk group, and 5.5% of patients in the baseline low-risk group. At multivariable analysis incomplete revascularization was an independent predictor of high Lp(a) variability (OR 2.22; 95% CI 1.14-4.31; p 0.02) while female sex, and age-adjusted menopause showed a trend (OR 1.92; 95% CI 0.93-4.00; p 0.08 and OR 11.18; 95% CI 0.79-157.58; p 0.07, respectively) without reaching formal statistical significance. The median absolute changes from baseline to 4-month and from baseline to 5-years follow-up were 7.9 mg/dL (IQR 3.0-18.9) and 10.7 mg/dL (IQR 3.0-21.7), respectively. Concordance between 4- and 8-month Lp(a) measurements was excellent. Conclusions: Early post-ACS intra-individual variability in Lp(a) is common, mainly affecting risk reclassification in intermediate-risk patients. In those patients, early targeted repeat Lp(a) measurement may improve cardiovascular risk stratification, whereas mid- to long-term reassessment appears unnecessary.
- Open Access
- 5 February 2026
- Published by MDPI AG in Preprints.org
Impact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary Syndrome
Reducing residual cardiovascular risk following an acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACE) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) [Lp(a)] is a pro-inflammatory, pro-thrombotic and pro-atherosclerotic lipoprotein which seems to play a major role in the residual risk post ACS or atherosclerotic ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although its clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions of hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role Lp(a) as a major contributor to residual cardiovascular risk following ACS.
- 5 February 2026
- Published by MDPI AG in Preprints.org
Open AccessImpact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary Syndrome
Reducing residual cardiovascular risk following an acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACE) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) [Lp(a)] is a pro-inflammatory, pro-thrombotic and pro-atherosclerotic lipoprotein which seems to play a major role in the residual risk post ACS or atherosclerotic ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although its clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions of hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role Lp(a) as a major contributor to residual cardiovascular risk following ACS.
- Open Access
- 25 January 2026
- Published by Springer Nature in Research Square
Continuous Glucose Monitoring Trajectories in Patients with Acute Coronary Syndrome
Background Continuous glucose monitoring (CGM) captures dysglycaemia and glycaemic variability after acute coronary syndrome (ACS), but patient-level trajectories from early recovery to mid-term follow-up—particularly in people without diabetes—remain insufficiently characterised. Methods In this prospective multicentre observational study (ORACLE programme), consecutive high-risk ACS patients wore a FreeStyle Libre 3/3 Plus sensor for 14–15 days near discharge and again at ~ 4 months. We quantified CGM time-in-range metrics (70–180 mg/dL and tight range 70–140 mg/dL), time above/below range, and variability/risk indices, including within-day profiles. Clinically relevant changes were categorised using pre-specified thresholds, and predictors of worsening were explored using multivariable models. Results Among 274 enrolled patients, 213 had analyzable baseline CGM recordings meeting quality criteria. Early post-ACS mean time-in-range 70–180 was 85.7 ± 21.4%, time in tight range 70–140 was 69.6 ± 27.7%, time above range > 180 was 12.8 ± 21.5%, and time below range < 70 was 1.5 ± 3.3% (mean glucose 131.4 ± 35.6 mg/dL; glucose management indicator 6.4 ± 0.8%). CGM demonstrated marked inter-individual heterogeneity and a reproducible late-morning (10:00–12:00) vulnerability window with lower range time and higher hyperglycaemic exposure, consistent across diabetes status and similar on weekdays and weekends; adverse CGM profiles were more prominent in patients with diabetes, older individuals, and women. Although CGM parameters improved modestly over the initial monitoring period, overall control deteriorated from baseline to ~ 4 months, including in patients without diabetes. Tight-range time decreased by 3.8% (95% CI − 6.67 to − 0.99; p = 0.0077) and mean glucose increased by 3.85 mg/dL (p = 0.035), accompanied by worsening variability and risk indices. Across CGM endpoints, ~ 20–40% of patients showed a worsening trajectory (20.2% by broad time-in-range thresholds); higher comorbidity burden clustered with deterioration, with hypertension and COPD independently associated with tight-range worsening. Conclusions After ACS, CGM reveals substantial inter-individual heterogeneity and a reproducible late-morning vulnerability window. From discharge to mid-term follow-up, deterioration—also affecting patients without diabetes—may be preferentially detected by tight-range and variability/risk metrics that traditional monitoring of blood glucose and static measures such as HbA1c may overlook, supporting CGM-informed phenotyping to refine post-ACS metabolic surveillance.
- 25 January 2026
- Published by Springer Nature in Research Square
Open AccessContinuous Glucose Monitoring Trajectories in Patients with Acute Coronary Syndrome
Background Continuous glucose monitoring (CGM) captures dysglycaemia and glycaemic variability after acute coronary syndrome (ACS), but patient-level trajectories from early recovery to mid-term follow-up—particularly in people without diabetes—remain insufficiently characterised. Methods In this prospective multicentre observational study (ORACLE programme), consecutive high-risk ACS patients wore a FreeStyle Libre 3/3 Plus sensor for 14–15 days near discharge and again at ~ 4 months. We quantified CGM time-in-range metrics (70–180 mg/dL and tight range 70–140 mg/dL), time above/below range, and variability/risk indices, including within-day profiles. Clinically relevant changes were categorised using pre-specified thresholds, and predictors of worsening were explored using multivariable models. Results Among 274 enrolled patients, 213 had analyzable baseline CGM recordings meeting quality criteria. Early post-ACS mean time-in-range 70–180 was 85.7 ± 21.4%, time in tight range 70–140 was 69.6 ± 27.7%, time above range > 180 was 12.8 ± 21.5%, and time below range < 70 was 1.5 ± 3.3% (mean glucose 131.4 ± 35.6 mg/dL; glucose management indicator 6.4 ± 0.8%). CGM demonstrated marked inter-individual heterogeneity and a reproducible late-morning (10:00–12:00) vulnerability window with lower range time and higher hyperglycaemic exposure, consistent across diabetes status and similar on weekdays and weekends; adverse CGM profiles were more prominent in patients with diabetes, older individuals, and women. Although CGM parameters improved modestly over the initial monitoring period, overall control deteriorated from baseline to ~ 4 months, including in patients without diabetes. Tight-range time decreased by 3.8% (95% CI − 6.67 to − 0.99; p = 0.0077) and mean glucose increased by 3.85 mg/dL (p = 0.035), accompanied by worsening variability and risk indices. Across CGM endpoints, ~ 20–40% of patients showed a worsening trajectory (20.2% by broad time-in-range thresholds); higher comorbidity burden clustered with deterioration, with hypertension and COPD independently associated with tight-range worsening. Conclusions After ACS, CGM reveals substantial inter-individual heterogeneity and a reproducible late-morning vulnerability window. From discharge to mid-term follow-up, deterioration—also affecting patients without diabetes—may be preferentially detected by tight-range and variability/risk metrics that traditional monitoring of blood glucose and static measures such as HbA1c may overlook, supporting CGM-informed phenotyping to refine post-ACS metabolic surveillance.